Renalytix AI PLC Stifel 2020 Healthcare Conference

TIDMRENX

Renalytix AI PLC

13 November 2020

Renalytix AI plc

("RenalytixAI" or the "Company")

RenalytixAI to Participate in the Stifel 2020 Healthcare Conference

NEW YORK, November 13, 2020 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care , today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference.

RenalytixAI's management is scheduled to present on Tuesday, November 17 at 10:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at www.investors.renalytixai.com .

For further information, please contact:

 
Renalytix AI plc                                       www.renalytixai.com 
James McCullough, CEO                                      Via Walbrook PR 
 
Stifel (Nominated Adviser, Joint Broker                 Tel: [phone] 
 ) 
Alex Price / Nicholas Moore 
 
Investec Bank plc (Joint Broker)                        Tel: [phone] 
Gary Clarence / Daniel Adams 
 
Walbrook PR Limited         Tel: [phone] or [e-mail] 
Paul McManus / Lianne Cawthorne                 Mob: [phone] / 07584 
                                                                   391 303 
 
 

About Kidney Disease

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com .

Disclosure Information

Renalytix AI plc uses filings with the Securities and Exchange Commission, its website ( www.renalytixai.com ), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAEAFFAFDNEFAA

(END) Dow Jones Newswires

November 13, 2020 02:00 ET (07:00 GMT)